Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults Up to the Age of 70 Years

BACKGROUND: Current AML risk stratification relies on genetic data (cytogenetics and molecular characteristics) and minimal residual disease (MRD) assessment. This approach allows optimizing the post-remission allocation to chemotherapy only or hematopoietic cell transplantation (HCT). We investigated the feasibility and results of a prospective risk-adapted phase II trial of intensive chemotherapy followed or not by autologous or allogeneic HCT based on these criteria.